# A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia

> **NCT07722728** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Bostal Drug Delivery Co., Ltd** · enrollment: 84 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** 30 mg B2227
- **DRUG:** 70 mg B2227
- **DRUG:** 150 mg B2227
- **DRUG:** Vraylar® 1.5 mg
- **DRUG:** Vraylar® 3.0 mg
- **DRUG:** Vraylar® 4.5 mg
- **DRUG:** Vraylar® 6.0 mg

## Key facts

- **NCT ID:** NCT07722728
- **Lead sponsor:** Bostal Drug Delivery Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-08
- **Final completion:** 2027-12
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722728, "A Study to Investigate Pharmacokinetics, Safety, and Tolerability of B2227 Extended-Release Injectable Suspension and Vraylar® in Participants With Schizophrenia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*